Key points are not available for this paper at this time.
Our objective was to establish consensus on (1) which patients with plaque psoriasis and limited skin involvement (body surface area BSA 3 or Physician Global Assessment Score of ≥2 after 8 weeks treatment. Our Delphi panel proposes criteria to help physicians identify patients with psoriasis and limited skin involvement who would benefit from systemic therapy and suggests a definition for topical therapy 'failure' which could indicate a move to systemic treatment is warranted.
Morita et al. (Wed,) studied this question.